Brought to you by 
Biogen licenses psoriasis candidate from Fumapharm
03 Mar 2020
Executive Summary
Privately held pharmaceutical company Fumapharm AG (psoriasis therapeutics) licensed Biogen (autoimmune and cancer therapeutics) exclusive worldwide development and marketing rights (excluding Germany) to its immunomodulatory compound to treat psoriasis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen licenses psoriasis candidate from Fumapharm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice